Colloidal Oatmeal: An FDA-Recognized Skin Protectant With a Long History

Few skincare ingredients can claim to have been used for thousands of years, recognized by the U.S. Food and Drug Administration as a safe and effective drug, and validated by modern peer-reviewed research. Colloidal oatmeal is one of them. Made from finely ground oats, this humble ingredient has earned its place as one of the most trusted active ingredients in dermatology.

This article is an educational overview of colloidal oatmeal: where it comes from, what it is made of, why it is regulated as an over-the-counter drug, and what the science says about how it works on the skin.

---

Quick Facts

Property	Description
Common name	Colloidal oatmeal
Source plant	Avena sativa L., 1753 (common oat) [1]
Family	Poaceae (grasses)
Definition	Finely ground oat grain processed so that it disperses uniformly in water
U.S. regulatory status	FDA-recognized OTC skin protectant active ingredient (21 CFR 347.10(f)) [2]
Minimum concentration	0.007 percent (alone); 0.003 percent in combination with mineral oil [2]
Approved label uses	Temporarily protects and helps relieve minor skin irritation and itching due to rashes, eczema, poison ivy/oak/sumac, and insect bites [3]
Final monograph published	June 4, 2003 [4]
Key bioactive components	Starches, beta-glucans, proteins, lipids, avenanthramides, phenolic acids [5]

---

A Brief Natural History

The common oat, Avena sativa, was formally described by Carl Linnaeus in his 1753 Species Plantarum, the founding work of modern botanical nomenclature [1]. Genetically, oats are a hexaploid grass, meaning they carry six sets of chromosomes, the result of ancient natural hybridization events in their evolutionary past [6].

Unlike wheat and barley, which were domesticated in the Fertile Crescent roughly 10,000 years ago, oats arrived on the scene much later. They started as a weed growing among other cereal crops in the Near East and were gradually domesticated as those crops spread northwest into the cooler, wetter conditions of Bronze Age Europe, roughly 3,000 to 4,000 years ago [7]. Oats thrived where wheat struggled, and they eventually became a staple grain across northern Europe and the British Isles.

The medicinal use of oats on the skin is older still. Greek and Latin texts describe oat preparations applied topically for skin conditions [8]. In modern times, the term "colloidal oatmeal" was coined and commercialized in 1945, when the brand Aveeno introduced a finely milled oat product designed to disperse evenly in bathwater rather than sinking to the bottom [8]. The word "colloidal" simply refers to particles small enough to remain suspended in liquid rather than settling out.

---

What Colloidal Oatmeal Actually Is

Colloidal oatmeal is not a chemical extract or an isolated compound. It is the whole oat grain, mechanically ground to a very fine particle size, with the entire complex chemistry of the grain preserved in the powder. By definition under the United States Pharmacopeia (USP), it is derived from Avena sativa or closely related Avena species, milled and processed so that it forms a stable suspension in water [9].

The composition of colloidal oatmeal has been characterized in detail. It contains roughly 65 to 85 percent starch, 15 to 20 percent protein, 3 to 11 percent lipids, about 5 percent fiber, and roughly 5 percent beta-glucan [5]^, [8]. Compared to other cereal grains, oats have an unusually high fat content, with most of those lipids being unsaturated triglycerides [5]. The grain also contains phenolic compounds, vitamin E (alpha-tocopherol), saponins (avenacosides and avenacins), and trace minerals.

This complete, multi-component nature is part of what makes colloidal oatmeal unusual. Most active drug ingredients are single, purified molecules. Colloidal oatmeal is a whole-grain preparation in which several different molecular families contribute different functions at the same time.

---

The Bioactive Components and What They Do

Decades of laboratory and clinical research have identified several distinct categories of compounds in oats that contribute to the way colloidal oatmeal interacts with skin.

Beta-glucans. Oat beta-glucan is a soluble dietary fiber composed of (1→3),(1→4)-linked beta-D-glucose units [10]. On the skin, it acts as a hydrocolloid, meaning it binds water and forms a thin film that helps trap moisture in the outer skin layer (the stratum corneum) [5].

Starches. The high starch content of oats also contributes to water binding and forms part of the protective film when colloidal oatmeal is applied to skin [5].

Avenanthramides. These are a family of phenolic compounds that are essentially unique to oats among cereal grains. They occur at roughly 300 parts per million in whole oat grain [11]. Their identification as the principal anti-inflammatory phytochemicals of oats was published in 2008 by researchers at Johnson and Johnson, who showed in cultured human keratinocytes (skin cells) that avenanthramides inhibit the activity of NF-kappaB, a master switch that controls inflammatory gene expression [11].

Phenolic acids and flavonoids. Oats also contain ferulic acid, caffeic acid, and various flavonoids, which contribute antioxidant activity and have been reported to absorb some ultraviolet wavelengths [9].

Lipids and tocopherols. The unsaturated triglycerides in oats contribute emollient (skin-softening) properties, while alpha-tocopherol (vitamin E) provides additional antioxidant activity [5].

Saponins. Oats contain saponins called avenacins and avenacosides, which have a soap-like structure and contribute mild cleansing properties [8].

---

The FDA Monograph: Why Colloidal Oatmeal Is an OTC Drug

In the United States, the Food and Drug Administration regulates over-the-counter drugs through a system called the OTC Monograph process. A monograph is essentially a recipe book published by the FDA: it lists the active ingredients that have been reviewed and found to be generally recognized as safe and effective (GRASE) for a specific use, along with the conditions under which they may be marketed without a new drug application.

The relevant monograph for colloidal oatmeal is the Final Monograph for Skin Protectant Drug Products for Over-the-Counter Human Use, published in the Federal Register on June 4, 2003 [4]. This monograph is now codified at 21 CFR Part 347. Within it, colloidal oatmeal is listed as a Category I (safe and effective) skin protectant active ingredient at 21 CFR 347.10(f), with a minimum concentration of 0.007 percent when used alone [2].

The monograph also specifies the language manufacturers may use on their labels. Under 21 CFR 347.50(b)(4), products containing colloidal oatmeal may state that they "temporarily protect and help relieve minor skin irritation and itching due to" one or more of the following: rashes, eczema, poison ivy/oak/sumac, or insect bites [3]. These claims are not marketing language; they are the specific indications the FDA has determined are supported for this ingredient.

In 2021, the FDA reissued the skin protectant rules as Administrative Order OTC Monograph M016, retaining the same provisions for colloidal oatmeal [12]. The result is that any product properly formulated to meet the monograph's requirements is legally an over-the-counter drug, not just a cosmetic, and may carry a Drug Facts panel describing the relevant uses.

---

What Modern Research Has Found

The clinical and laboratory literature on colloidal oatmeal has grown substantially in recent decades. Notable findings from peer-reviewed studies include:

• A 2008 study in Archives of Dermatological Research demonstrated that avenanthramides inhibit NF-kappaB activation in human skin cells at concentrations as low as 1 part per billion, providing a molecular explanation for the anti-itch and anti-inflammatory effects long associated with oat [11].
• A 2012 review in the Indian Journal of Dermatology, Venereology and Leprology compiled the dermatologic literature on colloidal oatmeal, including effects on inflammatory cytokine release, histamine signaling, and skin barrier function [5].
• A 2015 paper in the Journal of Drugs in Dermatology reported that colloidal oatmeal extracts induced the expression of skin barrier-related genes, including those involved in epidermal differentiation, tight junction formation, and lipid regulation, and demonstrated pH-buffering capacity [13].
• A 2020 randomized controlled trial in the Journal of Drugs in Dermatology compared a 1 percent colloidal oat eczema cream to a standard moisturizer in 61 patients with mild-to-moderate atopic dermatitis. After 14 days, the colloidal oat cream group showed significant improvements in skin pH, skin barrier function, and skin hydration, along with shifts in the skin microbiome toward greater diversity [14].

It is important to read this list as what has been studied, not as a list of guaranteed results from any specific product. Each formulation must be evaluated on its own merits.

---

A Note on Safety

The Cosmetic Ingredient Review (CIR) Expert Panel evaluated Avena sativa-derived ingredients, including colloidal oatmeal, in its safety assessment of oat-derived cosmetic ingredients [9]. Despite the very widespread use of colloidal oatmeal in personal care products, reports of allergic contact dermatitis or contact urticaria are uncommon, and when they occur they are generally mild [8]. As with any topical ingredient, individual sensitivities are possible, and patch testing is recommended for anyone with a known oat or grass allergy.

---